Realtime | Geld | Brief | Zeit |
---|---|---|---|
31,670 | 31,810 | 17.03. | |
31,555 | 31,835 | 17.03. |
Stück | Geld | Kurs | Brief | Stück |
---|---|---|---|---|
31,585 | 642 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
0 | 1 | 642 |
Uhrzeit | Aktienkurs | Stück |
---|---|---|
17:35:48 | 31,585 | 329 |
17:30:29 | 31,535 | 88 |
17:23:20 | 31,580 | 38 |
17:21:07 | 31,550 | 45 |
17:17:10 | 31,580 | 4 |
17:11:51 | 31,535 | 30 |
17:07:39 | 31,570 | 6 |
17:04:58 | 31,555 | 31 |
17:04:04 | 31,490 | 186 |
17:03:41 | 31,545 | 6 |
17:00:35 | 31,525 | 20 |
17:00:35 | 31,525 | 100 |
16:59:57 | 31,520 | 84 |
16:59:57 | 31,520 | 100 |
16:58:18 | 31,525 | 10 |
16:58:18 | 31,525 | 40 |
16:51:52 | 31,550 | 201 |
16:51:15 | 31,530 | 3 |
16:38:09 | 31,350 | 6 |
16:36:00 | 31,390 | 4 |
Tagesumsatz Xetra | -0,080 -0,25 % | 9.265 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Moderna Stock: Is MRNA Underperforming the Healthcare Sector? | 19 | Barchart.com | ||
Sa | Down 93%, Is It Finally Time to Buy Moderna? | 33 | The Motley Fool | ||
Do | Is Moderna Stock A Sell As RFK Jr. Reportedly Mulls A Massive Funding Pull? | 47 | Investor's Business Daily | ||
Do | Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings) | 24 | Benzinga.com | ||
MODERNA Aktie jetzt für 0€ handeln | |||||
Mi | Moderna CEO Stéphane Bancel scored pay bump in 2024 despite revenue decline and missed sales target | 34 | FiercePharma |
Zeit | Aktuelle Nachrichten | Medien | ||
---|---|---|---|---|
Mo | Nicht Evotec: Steht diese Biotech-Aktie jetzt vor einer Kursexplosion? | FinanzNachrichten.de | © Foto: SpaceX auf UnsplashFür sein Alzheimer-Medikament Aducanumab wurde das US-Biotechunternehmen Biogen vor einigen Jahren noch gefeiert. Eine umstrittene Zulassung durch die US-Gesundheitsbehörde... ► Artikel lesen | |
Mo | Hemostemix Inc.: Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated... ► Artikel lesen | |
00:42 | Telix Pharmaceuticals Limited: Illuccix Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America | PR Newswire | MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian... ► Artikel lesen | |
04:12 | BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update | PR Newswire | VANCOUVER, BC, March 17, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is providing this bi-weekly update on the status of... ► Artikel lesen | |
Mo | BioArctic receives Orphan Drug Designation for exidavnemab the US | PR Newswire | STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug... ► Artikel lesen |